Manufacturing Strategies for Generics and Branded Drugs Converge

Generic drugs manufacturers and manufacturers of branded drugs are reassessing their manufacturing strategies in light of tightening competition in the sector, according to a recent report by Enrico T. Polastro, v.p. and senior industry specialist for Arthur D. Little Benelux (Brussels). Typically, generic drugs manufacturers outsource their bulk manufacturing, while branded drugs producers have retained much of their manufacturing in-house. The two distinct models are now converging as producers attempt to gain competitive edge through enhanced bulk ingredients...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers